Alpha Tau Medical’s (DRTS) “Buy” Rating Reaffirmed at HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $9.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 287.93% from the stock’s previous close.

Separately, Piper Sandler restated an “overweight” rating and set a $7.00 target price on shares of Alpha Tau Medical in a report on Thursday, August 15th.

Alpha Tau Medical Stock Up 1.1 %

DRTS stock opened at $2.32 on Friday. Alpha Tau Medical has a twelve month low of $1.75 and a twelve month high of $3.40. The company has a market cap of $161.63 million, a price-to-earnings ratio of -5.40 and a beta of 0.77. The company has a quick ratio of 11.60, a current ratio of 10.99 and a debt-to-equity ratio of 0.08. The business has a 50 day moving average price of $2.28 and a two-hundred day moving average price of $2.30.

Institutional Trading of Alpha Tau Medical

A number of hedge funds have recently made changes to their positions in DRTS. Aptus Capital Advisors LLC raised its stake in Alpha Tau Medical by 83.7% in the 2nd quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock valued at $56,000 after acquiring an additional 10,000 shares during the period. Financial Guidance Group Inc. lifted its stake in shares of Alpha Tau Medical by 83.7% during the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after buying an additional 10,000 shares during the last quarter. Caprock Group LLC bought a new stake in shares of Alpha Tau Medical during the 2nd quarter worth about $59,000. Finally, Levin Capital Strategies L.P. raised its holdings in Alpha Tau Medical by 2.6% in the 1st quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock valued at $999,000 after acquiring an additional 8,641 shares during the period. 2.65% of the stock is owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.